Profile data is unavailable for this security.
About the company
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
- Revenue in INR (TTM)19.16bn
- Net income in INR2.90bn
- Incorporated1940
- Employees6.37k
- LocationF D C Ltd142-148, S.V. Road, Jogeshwari (W)MUMBAI 400053IndiaIND
- Phone+91 2 226739100
- Fax+91 2 226300614
- Websitehttps://www.fdcindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 6.05bn | 1.37bn | 43.81bn | 338.00 | 31.90 | -- | 25.23 | 7.24 | 12.28 | 12.28 | 54.16 | -- | -- | -- | -- | 17,892,400.00 | -- | 11.87 | -- | 13.19 | 76.42 | 72.20 | 23.02 | 25.79 | -- | 59.04 | -- | 7.49 | 2.13 | 6.44 | -11.66 | 3.24 | 28.32 | 14.87 |
| Aarti Drugs Ltd | 26.51bn | 1.80bn | 46.35bn | 1.50k | 25.83 | -- | 20.08 | 1.75 | 19.52 | 19.52 | 287.30 | -- | -- | -- | -- | 17,673,360.00 | -- | 9.91 | -- | 16.40 | 32.25 | 22.33 | 6.81 | 8.23 | -- | 8.29 | -- | 5.53 | 9.14 | 16.56 | -18.89 | 15.11 | 17.20 | 31.95 |
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 47.27bn | 1.40k | 24.30 | -- | 17.86 | 2.58 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 53.20bn | 1.03k | -- | -- | 50.04 | 4.74 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 55.00bn | 838.00 | 38.05 | -- | 34.60 | 6.77 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 66.71bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| F D C Ltd | 19.16bn | 2.90bn | 74.36bn | 6.37k | 25.91 | -- | 22.62 | 3.88 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 78.01bn | 1.40k | 24.42 | -- | 20.15 | 3.71 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| Procter & Gamble Health Ltd | 12.37bn | 2.27bn | 78.60bn | 1.41k | 34.68 | 9.75 | 31.14 | 6.35 | 136.55 | 136.55 | 745.23 | 485.49 | 1.15 | 2.51 | 10.40 | 8,791,756.00 | 21.02 | -- | 27.67 | -- | 69.97 | -- | 18.32 | -- | 2.79 | 383.03 | 0.0132 | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 39.53bn | -1.52bn | 80.57bn | 2.85k | -- | -- | 136.21 | 2.04 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 83.52bn | 407.00 | -- | -- | -- | 78.29 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Wockhardt Ltd | 27.76bn | -5.01bn | 88.01bn | 2.74k | -- | -- | -- | 3.17 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 89.47bn | 1.57k | 28.22 | -- | 23.94 | 5.66 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 99.85bn | 1.82k | 21.23 | 4.28 | 19.04 | 4.37 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Granules India Ltd | 45.26bn | 3.95bn | 102.78bn | 3.65k | 25.99 | -- | 17.18 | 2.27 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
| Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 102.94bn | 777.00 | 23.64 | -- | 21.03 | 6.31 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
Data as of Apr 26 2024. Currency figures normalised to F D C Ltd's reporting currency: Indian Rupee INR
9.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 13 Jun 2023 | 8.44m | 5.18% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 4.29m | 2.64% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 867.23k | 0.53% |
| Bandhan Asset Management Co. Ltd.as of 31 Mar 2024 | 507.12k | 0.31% |
| Tata Asset Management Ltd.as of 31 Mar 2024 | 471.28k | 0.29% |
| Samco Asset Management Pvt. Ltd.as of 31 Mar 2024 | 429.10k | 0.26% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 342.43k | 0.21% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 302.71k | 0.19% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 144.13k | 0.09% |
| ITI Asset Management Ltd. (India)as of 31 Mar 2024 | 69.87k | 0.04% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
